Tom O’Lenic joins RedShiftBio as Chief Executive Officer
March 7, 2024, 09:00 AM ET BOXBOROUGH MA. --RedShiftBioAnalytics, Inc. (RedShiftBio), a provider of innovative analytical solutions for the measurement of protein characterization and protein concentration used in biotherapeutic drug development and manufacturing, proudly announces the appointment of Tom O’Lenic as its new Chief Executive Officer (CEO). With over two decades of experience in commercial leadership and management roles, O’Lenic brings a wealth of expertise in driving business growth from start-upstages to favorable outcomes, with a strong emphasis on commercial strategy and execution and a history of creating over $1.5B of exit values as a C-Level executive.
O’Lenic’s career includes notable positions such as Chief Commercial Officer at Unchained Labs and Advanced Cell Diagnostics (ACD), as well as Senior Vice President and General Manager at Molecular Devices. His tenure at these organizations saw exponential revenue growth and successful exits, underscoring his ability to navigate complex commercial landscapes and drive tangible results.
